Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

NIOSHTIC-2 Publications Search

Search Results

Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Gordon Wright-J; Quinn-CP; Shadomy-S; Messonnier-N; Advisory Committee on Immunization Practices; ACIP Anthrax Vaccine Working Group
MMWR Recomm Rep 2010 Jul; 59(RR-06):1-30
These recommendations from the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations for anthrax vaccine adsorbed (AVA) (CDC. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2000;49:1--20; CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2002;51:1024--6) and reflect the status of anthrax vaccine supplies in the United States. This statement 1) provides updated information on anthrax epidemiology; 2) summarizes the evidence regarding the effectiveness and efficacy, immunogenicity, and safety of AVA; 3) provides recommendations for pre-event and preexposure use of AVA; and 4) provides recommendations for postexposure use of AVA. In certain instances, recommendations that did not change were clarified. No new licensed anthrax vaccines are presented. Substantial changes to these recommendations include the following: 1) reducing the number of doses required to complete the pre-event and preexposure primary series from 6 doses to 5 doses, 2) recommending intramuscular rather than subcutaneous AVA administration for preexposure use, 3) recommending AVA as a component of postexposure prophylaxis in pregnant women exposed to aerosolized Bacillus anthracis spores, 4) providing guidance regarding preexposure vaccination of emergency and other responder organizations under the direction of an occupational health program, and 5) recommending 60 days of antimicrobial prophylaxis in conjunction with 3 doses of AVA for optimal protection of previously unvaccinated persons after exposure to aerosolized B. anthracis spores.
Vaccines; Biological-warfare-agents; Biological-weapons; Infectious-diseases; Microorganisms; Bacterial-disease; Bacteria; Bacterial-infections; Epidemiology
Jennifer Gordon Wright, DVM, CDC, 1600 Clifton Road, NE; MS A-38; Atlanta, GA 30333
Publication Date
Document Type
Journal Article
Email Address
Fiscal Year
NTIS Accession No.
NTIS Price
Issue of Publication
NIOSH Division
Source Name
Morbidity and Mortality Weekly Report: Recommendations and Report